- Previous Close
0.242 - Open
0.242 - Bid 0.241 x --
- Ask 0.248 x --
- Day's Range
0.240 - 0.242 - 52 Week Range
0.201 - 0.620 - Volume
656,500 - Avg. Volume
1,866,410 - Market Cap (intraday)
312.406M - Beta (5Y Monthly) 3.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.760 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.
www.cloverbiopharma.comRecent News: 2197.HK
View MorePerformance Overview: 2197.HK
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2197.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2197.HK
View MoreValuation Measures
Market Cap
312.41M
Enterprise Value
29.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.79
Price/Book (mrq)
--
Enterprise Value/Revenue
0.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.50%
Return on Equity (ttm)
--
Revenue (ttm)
28.9M
Net Income Avi to Common (ttm)
-884.29M
Diluted EPS (ttm)
-0.760
Balance Sheet and Cash Flow
Total Cash (mrq)
480.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-214.6M